This Information Brief examines the opportunities and challenges for behavioral health providers under the Affordable Care Act (the ACA). With a particular focus on substance abuse, this brief considers three challenges: (1) The ACA Coverage Gap, (2) Providers' Lack of ACA Knowledge and Strategic Plans, and (3) The Need for Client Outreach & Enrollment. The brief offers solutions to providers' practical problems and calls attention to policy issues that require additional consideration or research.
This Information Brief examines the Affordable Care Act (the ACA)-- also known as health care reform or "ObamaCare"-- and its potential impact on substance abuse treatment. In particular, this brief considers the impact of the ACA's Medicaid expansion, Affordable Insurance Exchanges, and Essential Health Benefits (EHBs) on the healthcare market, anticipating the law's effects on the financing and provision of substance abuse treatment. The brief predicts that the influx of 27 newly insured individuals coupled with EHB and parity requirements will yield a considerable number of new substance abuse clients and trigger a notable shift in payers. These events, in turn, will drive further changes for both substance abuse treatment providers and clients, as the field moves toward new financial systems that emphasize integrated payment models.
Continue reading The Affordable Care Act: Shaping Substance Abuse Treatment
Delivered at the 2013 Utah Valley University Conference on Addiction, this presentation examines the non-medical use of prescription drugs and the Office of National Drug Control Policy's (ONDCP) strategies to curtail prescription drug abuse, notably examining Prescription Drug Monitoring Programs (PMPs) and the Drug Enforcement Administration's (DEA) Proposed Rule governing prescription drug takeback programs.
In particular, this presentation:
This presentation, delivered at the National Conference of Insurance Legislators' (NCOIL) annual meeting in Point Clear, Alabama, examines the non-medical use of prescription drugs (particularly opioids), the consequences of non-medical use, and the strategies currently available to combat such use.
Major Topics Include:
This 2011 U.S. Department of Justice National Drug Intelligence Center report-- prepared by Carnevale Associates, LLC. and Simeone Associates, Inc.-- examines the economic cost of illicit drug use in America, concluding that such use cost the U.S. $193 billion in 2007.
The report examines costs in three areas:
Continue reading The Economic Impact of Illicit Drug Use on American Society